RxDoctor Payments Data

Cari Wildharber, APRN

Family · Paducah, KYNPI 1134471113

Payments from drug & device makers

$10,241in general payments, 2019–2025

Across 494 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$930
  • AstraZeneca$738
  • Amgen$588
  • Pfizer$531
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$10,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,241 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$51,755
Medicare patients
236
Services billed
935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$89,272
MounjaroTirzepatide62$76,692
EliquisApixaban67$54,885
JardianceEmpagliflozin40$42,409
RybelsusSemaglutide13$23,254
FarxigaDapagliflozin Propanediol24$22,953
Nurtec OdtRimegepant Sulfate13$17,693
XareltoRivaroxaban15$17,240
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$9,891
LinzessLinaclotide14$8,441
Spiriva RespimatTiotropium Bromide12$6,142
SymbicortBudesonide/Formoterol Fumarate21$5,602
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$5,593
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$4,928
DexilantDexlansoprazole14$4,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,090$112,52688 claims
Lilly USA, LLCMounjaro$930$76,69262 claims
PfizerEliquis, Nurtec Odt$531$72,57880 claims
Boehringer IngelheimJardiance, Spiriva Respimat$278$48,55152 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$738$43,37474 claims
Johnson & JohnsonXarelto$130$17,24015 claims
AbbVieLinzess, Synthroid$1,802$9,73626 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$91$4,25914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →